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A one-year, randomized, double-blind study was con-
ducted in 80 patients with atopic dermatitis treated with 
tacrolimus ointment or a corticosteroid regimen (hydro-
cortisone acetate 1% ointment for head and neck, hydro-
cortisone butyrate 0.1% ointment for trunk and limbs) to 
compare efficacy and safety, and effects on Th2-reactivity. 
The study was completed by 36/40 patients in the tacroli-
mus group, and 31/40 patients in the corticosteroid group. 
In both groups affected body surface area, eczema area 
and severity index, and transepidermal water loss de-
creased at months 6 and 12. Tacrolimus was superior for 
all efficacy scores at month 6, and in the head and neck 
area at month 12. Recall antigen reactivity increased at 
month 12 in both groups. Adverse events were reported 
by 40/40 patients in the tacrolimus, and by 34/40 patients 
in the corticosteroid group. Long-term treatment with 
topical tacrolimus or a corticosteroid regimen improves 
atopic dermatitis and recall antigen reactivity, suggesting 
an improvement in the Th1/Th2-balance. Key words: ato-
pic dermatitis; hydrocortisone butyrate; randomized con-
trolled trial; recall antigen; tacrolimus ointment.
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Atopic dermatitis (AD) is an inflammatory skin condi-
tion that shows signs of decreased T-helper type 1 (Th1) 
and increased T-helper type 2 (Th2) immune reactivity. 
In patients with active AD this increases susceptibility 
to microbial infections of the skin, and increases serum 
levels of immunoglobulin E (S-IgE) (1). The decreased 
Th1 reactivity can be demonstrated as impaired reac-
tions in skin tests with recall antigens (2), which indi-
rectly measure delayed-type hypersensitivity. Patients 
receiving systemic immunosuppressive treatment also 
have impaired reactions (3), and are known to have 
increased susceptibility to infections and skin cancer 
(4, 5). We have previously observed an improvement in 
recall antigen reactions in an uncontrolled safety study 
with 48 adult AD patients treated for one-year with 
topical tacrolimus (6). To our knowledge there are no 
published studies on recall antigen reactions in patients 
with AD treated with topical corticosteroids.
Tacrolimus inhibits early gene transcription and acti-
vation of T cells. Topical tacrolimus (0.03% and 0.1% 
ointment) is indicated for the treatment of moderate-to-
severe AD, and efficacy has been demonstrated in adults 
and children (7, 8). Long-term safety of tacrolimus 
ointment has been investigated in trials of up to 4 years 
duration (9, 10), and no increase in skin infections, skin 
cancer, or lymphomas has been detected (11–14).
Topical corticosteroids have long been the first-line 
treatment for AD, but their use is limited by the wide 
distribution of steroid-responsive elements in various 
cells and tissues. Prolonged use can lead to signs of skin 
atrophy, such as striae, and telangiectasias, and even 
to systemic side-effects, including growth-restriction 
in children, and glaucoma. Topical corticosteroids are 
approved only for short-term use, and there are, to our 
knowledge, only a few published long-term (12 months) 
studies on treatment with topical corticosteroids in AD 
(15, 16).
To further investigate and compare the long-term 
efficacy and safety of 0.1% tacrolimus ointment and a 
corticosteroid regimen, we performed a randomized, 
double-blind, comparative study in patients with AD.
PATIENTS AND METHODS
Study design
A one-year, randomized, double-blind, comparative study of 
tacrolimus ointment vs. a corticosteroid regimen was conducted 
in a single centre in Helsinki, Finland. The study was approved 
by the local ethics committee, and all patients gave written 
informed consent. Some of the efficacy and safety data from 
this study were included in a published 6-month clinical study 
that included 972 patients from 57 centres (17).
Patients and methods
Adults (aged ≥ 18 years) with moderate-to-severe AD according 
to the Rajka & Langeland criteria (18) were randomized 1:1 
to treatment with 0.1% tacrolimus ointment (all affected body 
areas), or hydrocortisone acetate 1% ointment (head and neck) 
plus hydrocortisone butyrate 0.1% ointment (trunk and extremi-
ties). The ointment tubes were marked for treatment of either head 
and neck or trunk and limbs, and were identical in appearance in 
both groups. They were given to the patient and returned to the 
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investigator in sealed boxes, and thus the investigator could not 
assess the ointment bases. AD flares were treated twice-daily until 
7 days after clearance, and treatment resumed in the event of a 
recurrence or new flare. There was no limitation of ointment usage 
over 12 months. In the initial 6 months, assessments were made 
every month, and then at months 9 and 12. Prohibited therapies 
during the study included topical and systemic corticosteroids 
for the treatment of AD, topical and systemic antimicrobials 
influencing efficacy assessments, systemic antihistamines, coal 
tar, ultraviolet radiation treatments, hypnotics and sedatives, and 
systemic immunosuppressive agents. Patients were advised to 
minimize the exposure of treated areas to sunlight. 
The primary end-point was response rate after 3 months of 
treatment, defined as the proportion of patients with ≥ 60% im-
provement in modified Eczema Area and Severity Index (mEASI) 
score, which we regarded as clinically significant improvement. 
Key end-points included clinical efficacy and safety, transepider-
mal water loss (TEWL), recall antigen testing, and S-IgE.
Assessments
Efficacy measures in the study included affected body surface 
area (BSA), and the Eczema Area and Severity Index (EASI) and 
mEASI scores. The mEASI is similar to the EASI, but includes 
an additional assessment of itch. From the EASI score we se-
parately analysed the score for the head and neck area (eczema 
score for head and neck). Physician’s and patient’s assessment 
of global response, the response for the head and neck area, and 
adverse events were recorded throughout the study.
TEWL was measured at baseline and months 3, 6, 9 and 
12, in nine target regions (three on the upper limbs, two each 
on the head and trunk, and one on the neck and lower limbs). 
Measurements were made with an Evaporimeter EP1 (servoMed, 
Stockholm, Sweden) according to published guidelines (19).
Recall antigen testing was carried out using the Multitest 
CMI (Institute Mérieux, Lyon, France) at baseline, and months 
6 and 12. An eight-pronged applicator was used, containing 
seven antigens (tetanus, diphtheria, Streptococcus group C, 
tuberculin, Candida albicans, Trichophyton and Proteus) and 
one vehicle control (glycerol). Results were recorded as the 
Merieux score, which is the sum of the average diameters from 
positive reactions (induration at application site of ≥ 2 mm in 
diameter), and number of positive reactions.
S-IgE samples were collected at baseline, month 6 and month 12, 
and were measured by a fluorescence enzyme immunoassay (FEIA, 
CAP system; Pharmacia Diagnostics AB, Uppsala, Sweden).
Statistical analysis
Statistical analyses were performed with the statistical software 
package SPSS 13.0 for windows (SPSS Inc, Chicago, IL, USA). 
An intention-to-treat analysis was carried out for all data, using 
the last observation carried forward where appropriate. Changes 
in the variables before and after were tested with the Wilcoxon 
test; groups were compared using the Mann-Whitney test. 
Fisher’s exact test was used to compare the incidence of adverse 
events between the two treatment groups. Correlations between 
parameters were investigated using the Spearman test. A p-value 
of less than 0.05 was considered to be statistically significant.
RESULTS
Patients
The analyses included 80 patients (40 in each of 
the tacrolimus ointment and corticosteroid regimen 
groups). Baseline characteristics were well balanced 
between the two arms (Table I). The full 12-month 
study was completed by 36 patients (90.0%) in the 
tacrolimus ointment group and 31 patients (77.5%) in 
the corticosteroid regimen group. There were few dis-
continuations, but for those who did, the most common 
reason was lack of efficacy (tacrolimus ointment, n = 1, 
corticosteroid regimen, n = 4). The median number of 
days in the study was 363 in the tacrolimus ointment 
group, and 361 in the corticosteroid regimen group. 
The median numbers of treatment days were 255 and 
327, respectively.
Clinical efficacy
The proportion of patients with ≥ 60% improvement in 
mEASI at month 3 was similar for both groups: 77.5% 
(n = 31) in the tacrolimus group and 72.5% (n = 29) in 
the steroid group. Affected BSA, EASI and mEASI sco-
res improved in both treatment arms over 12 months of 
treatment. The improvement was significantly greater 
in the tacrolimus ointment group for each parameter 
at month 6 (Table I). This is consistent with the results 
Table I. Patient baseline demographics and efficacy parameters 
at baseline, and months 6 and 12
Tacrolimus 0.1% 
ointment (n = 40)
Corticosteroid  
regimen (n = 40)
Age (years), mean ± SD 29.2 ± 10.1 29.3 ± 10.7
Sex, n (%)
Male 9 (22.5) 10 (25.0)
Female 31 (77.5) 30 (75.0)
Duration of AD (years), mean ± SD 26.3 ± 10.2 27.4 ± 11.1
Severity of AD, n (%)
Moderate 18 (45.0) 19 (47.5)
Severe 22 (55.0) 21 (52.5)
Affected BSA %, median (Q1–Q3)
Baseline 58.3 (30.1–75.0) 62.0 (28.1–83.5)
Month 6 5.4 (1.5–28.4)*# 15.5 (5.6–48.8)*
Month 12 5.5 (1.9–42.3)* 12.8 (3.1–42.3)*
EASI score, median (Q1–Q3)
Baseline 21.3 (11.0–31.8) 20.1 (12.7–37.9)
Month 6 3.2 (1.4–9.1)*# 7.1 (3.0–17.9)*
Month 12 3.5 (1.7–12.0)* 6.4 (2.4–15.4)*
Eczema score for head and neck, median (Q1–Q3)
Baseline 18.0 (12.0–24.0) 20.5 (12.0–32.0)
Month 6 4.0 (1.3–8.0)*## 12.0 (4.0–20.0)*
Month 12 4.0 (2.0–11.3)*# 9.5 (4.0–20.8)*
TEWL (g/m2h), median (Q1–Q3)
Head and neck
Baseline 30.3 (20.6–41.7) 35.2 (22.8–48.1)
Month 6 14.5 (11.4–20.1)*## 20.7 (14.9–30.3)*
Month 12 14.5 (10.4–19.8)*# 18.5 (11.8–28.0)*
Trunk and limbs
Baseline 14.3 (9.5–19.4) 16.2 (11.4–23.3)
Month 6 9.0 (7.9–11.4)* 9.8 (7.0–13.3)*
Month 12 9.0 (6.7–11.7)* 8.3 (6.7–12.8)*
Intention-to-treat population. *p ≤ 0.001 vs. baseline, Wilcoxon test.
#p ≤ 0.05 vs. steroid, ##p ≤ 0.01 vs. steroid, Mann-Whitney test.
AD: atopic dermatitis; BSA: body surface area; EASI: Eczema Area and 
Severity Index; (Q1-Q3): interquartile range; TEWL: transepidermal water 
loss.
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from the large 6-month multi-centre study, in which the 
efficacy of tacrolimus ointment for these parameters 
was significantly greater than that of the corticosteroid 
regimen (p ≤ 0.01) (17). At month 12 the efficacy para-
meters for tacrolimus ointment were close to the month 
6 results, with a median affected BSA improvement 
of 91%. The efficacy parameters for the corticosteroid 
regimen continued to improve slightly between months 
6 and 12, with a final median affected BSA improve-
ment of 79%. No significant difference in the efficacy 
parameters could be seen between the groups at month 
12; this was probably due to the smaller difference in 
affected BSA between the groups at month 12, and the 
relatively small patient numbers.
At month 12, 57.5% (n = 23) of patients receiving 
tacrolimus were rated by their physician as having a 
response of “cleared or excellent” for the global evalua-
tion of clinical response, compared with 42.5% (n = 17) 
receiving the corticosteroid regimen (p = 0.26). When 
the head and neck region was considered separately, 
60.0% (n = 24) of the tacrolimus-, vs. 30.0% (n = 12) 
of the corticosteroid-treated patients were rated as 
“cleared or excellent” by the physician (p = 0.01). We 
also separately analysed the eczema score (area and 
individual signs) for the head and neck region, which 
represents 10% of the total EASI score. The scores were 
significantly lower in the tacrolimus group than in the 
steroid group at both month 6 (p ≤ 0.01) and month 12 
(p ≤ 0.05).
Transepidermal water loss
TEWL decreased from baseline in both tacrolimus- 
and steroid-treated patients at month 12 for both the 
combined sites on head and neck, and trunk and limbs 
(p < 0.001). TEWL values for head and neck at month 
12 were significantly lower in the tacrolimus group than 
in the steroid group (p = 0.04), which was in accordance 
with the lower eczema score for the head and neck in 
the tacrolimus group at month 12. TEWL for trunk and 
limbs did not differ between the treatment groups at 
month 12 (Table I).
Recall antigens
Both treatment groups experienced a significant in-
crease in the Merieux score from baseline to month 
12 (tacrolimus p = 0.001, steroid p = 0.04) (Fig. 1). No 
significant increase in the Merieux score could be seen 
in either group at month 6 (tacrolimus p = 0.21, steroid 
p = 0.19). The difference in the Merieux score between 
the groups was non-significant at month 12 (p = 0.4).
The number of positive antigen responses increased 
significantly in the tacrolimus ointment group after 12 
months of treatment (p = 0.003). In the corticosteroid 
regimen group there was a numerical, but non-signifi-
cant increase in the number of antigens (p = 0.09). The 
difference between the groups at month 12 was non-
significant (p = 0.46). 
Serum total IgE
S-IgE levels at baseline differed between the two 
groups despite that other patient demographics, such as 
disease severity and EASI, were well balanced. Base-
line median S-IgE was 659 kU/l in the tacrolimus group 
and 1523 kU/l in the corticosteroid group (p = 0.03). 
No significant decrease could be seen in either group at 
month 12. When all patients (tacrolimus ointment and 
corticosteroid treated) with at least 60% improvement 
in affected BSA at month 12 (n = 53) were analysed, 
median S-IgE decreased from 666 kU/l at baseline 
to 584 kU/l at month 12 (p = 0.02). In patients with 
at least 90% improvement in affected BSA at month 
12 (n = 29) median S-IgE decreased from 532 kU/l at 
baseline to 383 kU/l at month 12 (p = 0.009). S-IgE for 
all patients (n = 80) correlated with affected BSA at 
baseline (r = 0.40, p < 0.001) and at month 12 (r = 0.49, 
p < 0.001). There was an inverse correlation between 
S-IgE and recall antigens (Merieux score) for all pa-
tients (n = 80) at both baseline (r = –0.40, p < 0.001), 
and month 12 (r = –0.34, p = 0.002).
Safety
Adverse events occurred in 40 patients (100%) in the 
tacrolimus ointment arm and 34 patients (85.0%) in the 
corticosteroid arm. The difference between the treatment 
arms was statistically significant (p = 0.03), and was ac-
counted for mainly by the higher incidence of the well-
known application-site skin burning sensation with tacro-
limus ointment. The other common adverse events were 
flu syndrome and folliculitis. Flu syndrome was observed 
in 22 of the tacrolimus- and 16 of the steroid-treated 
patients during the study (p = 0.26), and folliculitis in 20 
Baseline        Month 12      Baseline      Month 12








 *p=0.04 vs. baseline
**p=0.001 vs. baseline
Fig. 1. Improvement of recall antigen reactions during treatment, as shown by 
the Merieux score. The results are presented as box-plots with the median value 
represented by a line across the box, and the mean by a smaller black box.
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and 17 of the tacrolimus- and steroid-treated patients, 
respectively (p = 0.65). Infections (e.g. viral and bacterial 
skin infections, folliculitis, and flu syndrome), which in 
the opinion of the investigator probably or possibly could 
be related to treatment, occurred during the study in 26 
patients (65.0%) receiving tacrolimus ointment and in 17 
(42.5%) receiving the corticosteroid regimen (p = 0.07). 
Two patients in the steroid group showed signs of skin 
atrophy; one with striae of legs, observed during the 
last 3 months of treatment, and one with subcutaneous 
hematomas, which resolved when treatment was ended. 
No serious adverse events or deaths were reported during 
the study in either treatment arm.
DISCUSSION
This one-year, double-blind study showed that tacrolimus 
treatment was significantly more effective than a cortico-
steroid regimen at month 6. At month 12 tacrolimus treat-
ment was numerically more effective, but the difference 
was non-significant, possibly due to the limited number 
of patients. Tacrolimus treatment was more effective 
than hydrocortisone acetate in the head and neck area at 
month 12, which was seen both for the head and neck 
eczema score and TEWL. Both treatments significantly 
decreased TEWL, probably by decreasing inflammation 
in the skin compartment. Active inflammation decreases 
filaggrin expression in the skin (20), which may lead to 
impaired barrier function (21). This allows environmental 
antigens and staphylococcal enterotoxins to penetrate the 
skin to further exacerbate the inflammation (22).
In this trial the use of study medication was not re-
stricted, and showed the high number of treatment days 
required to manage moderate-to-severe AD effectively. 
In the corticosteroid group the number of treatment days 
was higher than might be considered safe, and signs 
of skin atrophy were seen in two patients. A previous 
12-month study with a medium-potency corticosteroid, 
triamcinolone acetate, also reported skin atrophy and 
striae (15). Additional potentially harmful effects of cor-
ticosteroids include up-regulation of protease enzymes 
that could impair the skin barrier function (21). The main 
difference between topical corticosteroids and tacrolimus 
ointment is that long-term use of tacrolimus ointment 
does not decrease collagen synthesis, and thereby does 
not impair the structural integrity of the skin (23, 24). 
Tacrolimus ointment can be used over the longer term, 
or intermittently to control flares of AD. Two previous 
safety studies suggest that long-term intermittent use 
of topical tacrolimus in AD leads not only to improved 
clinical condition but also to a decrease in the use of ta-
crolimus ointment over a period of 12 months (10, 25).
The observed increase in the Merieux score after one 
year of topical tacrolimus or corticosteroid treatment 
reflects improvement in cell-mediated immunity as the 
signs and symptoms of AD improve. The current results 
are in direct contrast to those seen after systemic im-
munosuppressive treatment with cyclosporine, which is 
accompanied by a decrease in cell-mediated immunity 
(3). Tacrolimus and cyclosporine are both inhibitors 
of calcineurin, and the contrasting results on cellular 
immunity suggest that the effect of tacrolimus in AD 
is mainly in the skin.
Increased levels of IgE are common in AD, and reflect 
sensitization by environmental antigens and increased 
Th2 activity. Earlier studies have suggested a correlation 
between S-IgE levels and the degree of eczema (26). In 
this study we were able to confirm a correlation between 
S-IgE and BSA/EASI, and show an inverse correlation 
to recall antigens. Most importantly the results show that 
effective (at least 60% improvement) topical treatment 
of AD decreases S-IgE levels significantly. These results 
suggest that while a certain percentage improvement in 
affected BSA is reflected in a decrease of S-IgE level, 
the best results are obtained when the remaining affected 
BSA is as small as possible. The role of S-IgE in AD is 
not fully understood, but epidemiological data suggest 
a contributory role for immunological processes medi-
ated by IgE in the onset and course of AD, especially 
in patients with severe disease (27).
In conclusion, long-term treatment with 0.1% tacro-
limus ointment appears to be at least as effective as a 
corticosteroid regimen for the trunk and extremities, and 
more effective in the face and neck area. Both topical 
tacrolimus and corticosteroids increase skin recall acti-
vity, and decrease S-IgE in patients with good treatment 
response. These results suggest that skin inflammation 
in AD should be treated effectively, which could lead to 
an improvement in the Th1/Th2 balance in the skin, and 
to long-term improvement in the severity of the AD.
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